Bought $EXEL today on weakness, has a PDUFA date of 11/29 for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer.
PR: http://ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-newsArticle_Print&ID=1719697&highlight=
This one should still run over $6 if market remains strong.
No comments:
Post a Comment